Simultaneous determination of levocetirizine dihydrochloride and montelukast sodium in human plasma by LC–MS/MS: development, validation, and application to a human pharmacokinetic study

• Autorzy: Rashed Noha Salem , Nasr Zeinab Adel

Identyfikatory

DOI

10.1556/1326.2018.00439

• Języki publikacji: EN

Abstrakty

EN

Objectives: A simple, rapid, selective, and sensitive high-performance liquid chromatography–tandem mass spectrometry (LC–MS/MS) method was developed for the simultaneous determination of levocetirizine dihydrochloride and montelukast sodium in human plasma using fexofenadine hydrochloride as an internal standard. Method: Liquid–liquid extraction of both drugs and internal standard from plasma into ethyl acetate was used for sample preparation and analysis. Separation of both drugs and internal standard was achieved on an Inertsil ODS-3 (4.6 mm × 50 cm, dp 5 μm, particle size) column using an isocratic mobile phase of acetonitrile and 10 mM ammonium formate adjusted to pH 8 with 50 μL ammonium hydroxide in composition of 73:27 (v/v) at a flow rate of 0.7 mL/min. The LC–MS/MS was operated under the multiple reaction monitoring mode (MRM) using an electrospray ionization technique. Mass parameters were optimized to monitor transitions at m/z [M + H]+ 389.0 → 200.8 for levocetirizine dihydrochloride, m/z [M + H]+ 586.2 → 422.2 for montelukast sodium, and m/z [M + H]+ 502.2 → 466.0 for fexofenadine hydrochloride. Results: The method was found to be linear in the range of 1–500 ng/mL for both drugs. The intra-day and inter-day precision were in the range of 0.96–1.92% and 1.03–1.55%, respectively. Matrix effect was acceptable with %RSD < 15. Conclusion: The proposed method was validated and successfully applied for a pharmacokinetic study of both drugs in human plasma after oral administration of their pharmaceutical preparation.

Słowa kluczowe

EN

levocetirizine dihydrochloride; montelukast sodium; LC–MS/MS; validation; human plasma; pharmacokinetics

• Wydawca: University of Silesia in Katowice ; Akademiai Kiado
• Czasopismo: Acta Chromatographica
• Rocznik: 2019
• Tom: Vol. 31, no. 3
• Strony: 194--200
• Opis fizyczny: Bibliogr. 40 poz., rys., tab.

Twórcy

autor

Rashed Noha Salem

• Analytical Chemistry Department, Faculty of Pharmacy (Girls), Al-Azhar University, Cairo, Egypt

autor

Nasr Zeinab Adel

• Analytical Chemistry Department, Faculty of Pharmacy (Girls), Al-Azhar University, Cairo, Egypt

Bibliografia

• [1] Sweetman S. C. Martindale, the Extra pharmacopoeia 34th Ed. London, Pharmaceutical press, 2004.
• [2] Day, J. H.; Ellis, A. K.; Rafeiro, E. Drugs Today 2004, 40, 415.
• [3] Raghu, M. S.; Basavaiah, K. J. Assoc. Arab Univ. Basic Appl. Sci. 2012, 12, 33.
• [4] Hair, P. I.; Scott, L. J. Drugs 2006, 66, 973.
• [5] Lipi, F.; Parvin, Sh.; Islam, Md. R. Am. J. PharmTech Res. 2016, 6, 570.
• [6] Gunasakaran, S.; Rao, N.; Arunkumar, R.; Olaganathan, A. Biomirror, 2010, 1, 12.
• [7] Jain, N.; Jain, D. K.; Jain, R.; Patel, V. K. , Patel, P.; Jain, S. K. J. Appl. Pharm. Sci. 2016, 6, 10, 63.
• [8] Chaitanya, P. M. K.; Vidyasagar, G.; Sambasiva, R. K. R. S.; Induri, M.; Ramanjeneyulu, S. J. Appl. Pharm. Sci. 2011, 1, 95.
• [9] Bhusari, V. K.; Dhaneshwar, S. R. Int. J. Adv. Pharm. Sci. 2010, 1, 387.
• [10] Anandakumar, K.; Veerasundari, P. ISRN Spectrosc. 2014, 1.
• [11] Reddy, J. M.; Jeyaprakash, M. R.; Madhuri, K.; Meyyanathan, S. N.; Elango, K. Indian J. Pharm. Sci. 2011, 73, 320.
• [12] Shaikh, K. A.; Patil, A. T. Int. J. ChemTech Res. 2010, 2, 454.
• [13] Rao, A. S.; Pavankumar, K.; Satyanarayana, P.; Sastrya, G. S. W. J. Pharm. Pharm. Sci. 2015, 4, 1735.
• [14] Khedkar, A. N.; Veer, S. U.; Rakh, M. S.; Rao, J. R. Int. J. Pharm. Qua. Assur. 2014, 6, 24.
• [15] The Merck Index 14th Ed., Merck, Co., Inc., Rahway, USA, 2006.
• [16] Rathore, A. S.; Sathiyanarayanan, L.; Mahadik, K. R. Pharm. Anal. Acta 2010, 1, 1.
• [17] Gupta, V.; Matreja, P. S. J. Aller. Ther. 2010, 1, 1.
• [18] Ciebiada, M.; Ciebiada, M. G.; Kmieck, T.; Dumuske, L. M.; Gorski, P. J. Invest. Allergol. Clin. Immunol. 2008, 18, 343.
• [19] Van Hoecke, H.; Vandenbulcke, L.; Van Cauwenberge, P. Drugs 2007, 67, 2717.
• [20] Ciebiada, M.; Górska-Ciebiada, M.; DuBuske, L. M.; Górski, P. Ann. Allergy, Asthma, Immunol. 2006, 97, 664.
• [21] Kurowski, M.; Kuna, P.; Gorski, P. Allergy 2004, 59, 280.
• [22] Veeragoni, A. K.; Sindgi, V. M.; Satla, Sh. R. Pharm. Lett. 2016, 8, 320.
• [23] Singh, K.; Bagga, P.; Shakya, P.; Kumar, A.; Khalid, M.; Akhtar, J.; Arif, M. Int. J. Pharm. Sci. Res. 2015, 6, 4728.
• [24] Katteboina, M. Y.; Pilli, N. R.; Satla, Sh. R. Am. J. Pharm Tech Res. 2015, 5, 646.
• [25] Singh, R. M.; Saini, P. K.; Mathur, S. C.; Singh, G. N.; Lal, B. Indian J. Pharm. Sci. 2010, 72, 235.
• [26] Sane, R. T.; Menezes, A.; Moghe, M. M. A.; Gundi, G. J. Phys. Chem. 2004, 17, 75.
• [27] Alsarra, I.; Khalil, N. Y.; Sultan, M.; Al-Ashban, R.; Belal, F. Pharmazie 2005, 60, 823.
• [28] Pawar, V. , Pai, S.; Roa, G. K. Int. J. Pharma Sci. Res. 2008, 2, 152.
• [29] Ezzeldin, E.; Abo-Talib, N. F.; Tammam, M. H.; Shahat, A. A. Chem. Cent. J. 2014, 8, 1.
• [30] Radhakrishnaa, T.; Narasarajua, A. , Ramakrishnab, M.; Satyanarayana, A. J. Pharm. Biomed. Anal. 2003, 31, 359.
• [31] Vekaria, H. J.; Jat, K. R. J. Pharm. Sci. Bio-Sci. Res. 2015, 5, 475.
• [32] Haghighi, S.; Shapouri, M. R.; Amoli-Diva, M.; Pourghazi, K.; Afruzi, H. Iran J. Pharm. Res. 2013, 12, 303.
• [33] Smita, Sh. M. C. , Sharma, D. V.; Der Sharma, A. D. Pharm. Lett. 2010, 1, 489.
• [34] Ashokkumar, S.; Senthil, R. M; Perumal, P. Int. J. Pharm. Pharm. Res. 2009, 1, 8.
• [35] Suresh, R.; Manavalan, R.; Valliappan, K. Int. J. Drug Dev. & Res. 2012, 4, 173.
• [36] Ishaq, B. M. , Prakash, K. V. , Mohan, G. K. , Muneer, S.; Ahad, H. A. Indian Res. J. Pharm. Sci. 2015, 1, 18.
• [37] Wichitnithad, W. , Jithavech, P.; Sanphanya, K. , Vicheantawatchi, P.; Rojsitthisak, P. J. Cell Sci. 2015, 53, 1663.
• [38] Guidance for Industry-Bioanalytical Method Validation. Food and Drug Administration of the United States, US Department of Health and Human Services Center for Drug Evaluation and Research (CDET), Center for Veterinary Medicine (CVM) (2001).
• [39] Guideline on bioanalytical method validation. European Medicines Agency, Committee for Medicinal Products for Human Use (CHMP), 2011.
• [40] Kalakuntla, R. R.; Kumar, K. S. J. Pharm. Sci. Res. 2009, 1, 1.

Uwagi

PL

Opracowanie rekordu w ramach umowy 509/P-DUN/2018 ze środków MNiSW przeznaczonych na działalność upowszechniającą naukę (2019).